Phase 3 Clinical Trials With Primary Completion Dates in December 2023

This is a list of Phase 3 trials with primary completion dates in December 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALVO Alvotech 2023-12-01 Phase 3 NCT05155293 Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
ANGO AngioDynamics, Inc. 2023-12-01 Phase 3 NCT03899636 A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
ANVS Annovis Bio, Inc. 2023-12-01 Phase 3 NCT05357989 A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
APLT Applied Therapeutics, Inc. 2023-12-01 Phase 3 NCT04083339 Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
ASND Ascendis Pharma A/S 2023-12-01 Phase 3 NCT04615273 A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
AXSM Axsome Therapeutics, Inc. 2023-12-01 Phase 3 NCT05113745 A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
AXSM Axsome Therapeutics, Inc. 2023-12-01 Phase 3 NCT05550207 Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
BFRI Biofrontera Inc. 2023-12-01 Phase 3 NCT03573401 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
CING Cingulate Inc. 2023-12-01 Phase 3 NCT05286762 Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
CYTH Cyclo Therapeutics, Inc. 2023-12-01 Phase 3 NCT04860960 Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1
CZMWY Carl Zeiss Meditec AG 2023-12-01 Phase 3 NCT02685605 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
EQ Equillium, Inc. 2023-12-01 Phase 3 NCT05263999 A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
FOLD Amicus Therapeutics, Inc. 2023-12-01 Phase 3 NCT04138277 A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD
IONS Ionis Pharmaceuticals, Inc. 2023-12-01 Phase 3 NCT05139810 OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
ITCI Intra-Cellular Therapies, Inc. 2023-12-01 Phase 3 NCT04959032 Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
IVBXF Innovent Biologics, Inc. 2023-12-01 Phase 3 NCT04720716 A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
MMSI Merit Medical Systems, Inc. 2023-12-01 Phase 3 NCT03960008 Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
MNKD MannKind Corporation 2023-12-01 Phase 3 NCT04974528 Afrezza® INHALE-1 Study in Pediatrics
RDHL RedHill Biopharma Ltd. 2023-12-01 Phase 3 NCT04616924 RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
VNDA Vanda Pharmaceuticals Inc. 2023-12-01 Phase 3 NCT04028492 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis